618 results on '"Salama, Mohamed E."'
Search Results
2. CKD Progression Prediction in a Diverse US Population: A Machine-Learning Model
3. CXCL8/CXCR2 signaling mediates bone marrow fibrosis and is a therapeutic target in myelofibrosis
4. The Lineage-Defining Transcription Factors SOX2 and NKX2-1 Determine Lung Cancer Cell Fate and Shape the Tumor Immune Microenvironment
5. Development of a multiomics model for identification of predictive biomarkers for COVID-19 severity: a retrospective cohort study
6. Rules of engagement: Promoting academic-industry partnership in the era of digital pathology and artificial intelligence
7. Machine learning and augmented human intelligence use in histomorphology for haematolymphoid disorders
8. Phase 2 study of ruxolitinib and decitabine in patients with myeloproliferative neoplasm in accelerated and blast phase
9. MANIFEST: Pelabresib in Combination With Ruxolitinib for Janus Kinase Inhibitor Treatment-Naïve Myelofibrosis
10. Quantitative Image Analysis of Human Epidermal Growth Factor Receptor 2 Immunohistochemistry for Breast Cancer: Guideline From the College of American Pathologists
11. American Registry of Pathology Expert Opinions: Immunohistochemical evaluation of classic Hodgkin lymphoma
12. MPN-375 BET Inhibitor Pelabresib (CPI-0610) Combined With Ruxolitinib in Patients With Myelofibrosis – JAK Inhibitor-Naïe or With Suboptimal Response to Ruxolitinib – Preliminary Data From the MANIFEST Study
13. Supplementary Figure S5 from A Phase Ib Trial of AVID200, a TGFβ 1/3 Trap, in Patients with Myelofibrosis
14. Supplementary Table S3 from A Phase Ib Trial of AVID200, a TGFβ 1/3 Trap, in Patients with Myelofibrosis
15. Data from A Phase Ib Trial of AVID200, a TGFβ 1/3 Trap, in Patients with Myelofibrosis
16. A Phase Ib Trial of AVID200, a TGFβ 1/3 Trap, in Patients with Myelofibrosis
17. Predictive Markers Require Thorough Analytic Validation
18. Molecular Fingerprinting of Anatomically and Temporally Distinct B-Cell Lymphoma Samples by Next-Generation Sequencing to Establish Clonal Relatedness
19. US Food and Drug Administration Approval of Whole Slide Imaging for Primary Diagnosis: A Key Milestone Is Reached and New Questions Are Raised
20. Autocrine Tnf signaling favors malignant cells in myelofibrosis in a Tnfr2-dependent fashion
21. A phase 1 study of the Janus kinase 2 (JAK2)V617F inhibitor, gandotinib (LY2784544), in patients with primary myelofibrosis, polycythemia vera, and essential thrombocythemia
22. POWERPIINC (PreOperative Window of Endocrine TheRapy Provides Information to Increase Compliance) trial: Changes in tumor proliferation index and quality of life with 7 days of preoperative tamoxifen
23. Practical Approaches on CD30 Detection and Reporting in Lymphoma Diagnosis
24. Immunophenotypic and cytogenetic evolution patterns of the neoplastic plasma cells in multiple myeloma relapsed after stem cell transplant
25. Pegylated interferon Alfa-2a and hydroxyurea in polycythemia vera and essential thrombocythemia: differential cellular and molecular responses
26. Supplementary Table 1 from Nuclear–Cytoplasmic Transport Is a Therapeutic Target in Myelofibrosis
27. Supplementary Figure 6 from Nuclear–Cytoplasmic Transport Is a Therapeutic Target in Myelofibrosis
28. Supplementary Table 2 from Nuclear–Cytoplasmic Transport Is a Therapeutic Target in Myelofibrosis
29. Supplementary Table 3-8 from Nuclear–Cytoplasmic Transport Is a Therapeutic Target in Myelofibrosis
30. Supplementary Figure 3 from Nuclear–Cytoplasmic Transport Is a Therapeutic Target in Myelofibrosis
31. CXCL8/CXCR2 signaling mediates bone marrow fibrosis and represents a therapeutic target in myelofibrosis
32. Computational pathology in 2030: a Delphi study forecasting the role of AI in pathology within the next decade
33. Deep learning applications in visual data for benign and malignant hematological conditions: a systematic review and visual glossary
34. Therapy Effect: Impact on Bone Marrow Morphology
35. Polyomavirus large T antigen is prevalent in urothelial carcinoma post–kidney transplant
36. Dedication
37. Contributors
38. Progress in the Classification of Hematopoietic and Lymphoid Neoplasms
39. Primary Myelofibrosis
40. Poster: MPN-375 BET Inhibitor Pelabresib (CPI-0610) Combined With Ruxolitinib in Patients With Myelofibrosis-JAK Inhibitor-Naïve or With Suboptimal Response to Ruxolitinib-Preliminary Data From the MANIFEST Study
41. Chapter 56 - Progress in the Classification of Hematopoietic and Lymphoid Neoplasms: Clinical Implications
42. The future of computational pathology: expectations regarding the anticipated role of artificial intelligence in pathology by 2030
43. Interleukin-1 Receptor Antagonism Abrogates Acute Pressure Overload-Induced Murine Heart Failure
44. Optimized immunohistochemical panel to differentiate myeloid sarcoma from blastic plasmacytoid dendritic cell neoplasm
45. X-Ray of Excised Cancerous Breast Tissue Does Not Affect Clinical Biomarker Expression
46. Extracellular sodium and potassium levels modulate cardiac conduction in mice heterozygous null for the Connexin43 gene
47. Artificial Intelligence Enhances Diagnostic Flow Cytometry Workflow in the Detection of Minimal Residual Disease of Chronic Lymphocytic Leukemia
48. NEK2 Induces Drug Resistance Mainly through Activation of Efflux Drug Pumps and Is Associated with Poor Prognosis in Myeloma and Other Cancers
49. Clinical utility of next-generation sequencing in the diagnosis of hereditary haemolytic anaemias
50. Quantification of Estrogen Receptor Expression in Normal Breast Tissue in Postmenopausal Women With Breast Cancer and Association With Tumor Subtypes
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.